新桥生物Vis-101试验结果亮眼:平均BCVA改善超10个ETDRS字母,中位CST降低100-150微米

美股速递
Mar 09

新桥生物近日公布了其候选药物Vis-101的临床试验数据,结果显示其在治疗相关眼部疾病方面取得了显著成效。

数据显示,接受Vis-101治疗的患者群体,其最佳矫正视力出现了具有临床意义的提升,平均改善幅度超过了10个ETDRS字母。与此同时,患者的中位中心凹厚度也呈现出显著下降,降低范围在100至150微米之间。

这些积极的数据指标,为Vis-101后续的临床开发路径提供了有力的支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10